PMID- 34205421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210705
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 12
DP  - 2021 Jun 19
TI  - Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in 
      Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A 
      Multicenter Retrospective Cohort Study (LOTUS Study).
LID - 10.3390/jcm10122717 [doi]
LID - 2717
AB  - This multicenter retrospective cohort study compared the effectiveness and safety 
      of long-term tafluprost, travoprost, or latanoprost in patients with primary 
      open-angle glaucoma (POAG) or normal-tension glaucoma (NTG). Data were extracted 
      from electronic medical records of 300 patients treated with tafluprost, 
      travoprost, or latanoprost for >6 months. Propensity matching for age and sex was 
      used for effectiveness and safety comparisons. The primary endpoint was visual 
      field (VF) progression via mean deviation (MD) slope. Secondary endpoints were 
      change of MD, intraocular pressure, pattern standard deviation, VF index, and 
      advanced glaucoma intervention study score. Treatment-related adverse events 
      (AEs) were also compared between groups. Overall, 216 POAG or NTG patients were 
      matched into Match Set 1 (72 patients/group), and 177 NTG-only patients in Match 
      Set 2 (59 patients/group) according to: age (mean: 61, 62 years) and sex (male: 
      53, 56%). There were no statistically significant between-group differences 
      regarding MD slope (p = 0.413, p = 0.374 in Match Sets 1 and 2, respectively). 
      There were no significant between-group differences/tendencies regarding 
      secondary endpoints. No AEs were serious, and there were no significant 
      between-group differences regarding reported AEs. In patients with POAG or NTG, 
      long-term tafluprost, travoprost, or latanoprost showed similar effects. All 
      three prostaglandin analogs had good long-term safety profiles.
FAU - Kim, Joon-Mo
AU  - Kim JM
AUID- ORCID: 0000-0002-4543-043X
AD  - Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University 
      School of Medicine, Seoul 03181, Korea.
FAU - Sung, Kyung-Rim
AU  - Sung KR
AD  - Department of Ophthalmology, College of Medicine, University of Ulsan, Asan 
      Medical Center, Seoul 05505, Korea.
FAU - Kim, Hwang-Ki
AU  - Kim HK
AD  - Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research 
      Institute, Konyang University, Seoul 07301, Korea.
FAU - Park, Sang-Woo
AU  - Park SW
AD  - Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam 
      National University Medical School and Hospital, Gwangju 61469, Korea.
FAU - Lee, Eun-Ji
AU  - Lee EJ
AD  - Department of Ophthalmology, Seoul National University College of Medicine, Seoul 
      National University Bundang Hospital, Seongnam 13620, Korea.
FAU - Jeoung, Jin-Wook
AU  - Jeoung JW
AUID- ORCID: 0000-0002-1690-1239
AD  - Department of Ophthalmology, Seoul National University College of Medicine, Seoul 
      National University Hospital, Seoul 03080, Korea.
FAU - Park, Hae-Young Lopilly
AU  - Park HL
AD  - Department of Ophthalmology, Seoul St Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul 06591, Korea.
FAU - Ahn, Jaehong
AU  - Ahn J
AD  - Department of Ophthalmology, Ajou University School of Medicine, Suwon 16499, 
      Korea.
FAU - Yoo, Chungkwon
AU  - Yoo C
AD  - Department of Ophthalmology, Korea University College of Medicine, Seoul 02841, 
      Korea.
FAU - Kim, Chan-Yun
AU  - Kim CY
AUID- ORCID: 0000-0002-8373-9999
AD  - Institute of Vision Research, Department of Ophthalmology, Severance Hospital, 
      Yonsei University College of Medicine, Seoul 03722, Korea.
LA  - eng
GR  - NA/Santen Pharmaceutical Korea Co. Ltd./
PT  - Journal Article
DEP - 20210619
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8235659
OTO - NOTNLM
OT  - glaucoma
OT  - latanoprost
OT  - prostaglandin analogs
OT  - tafluprost
OT  - travoprost
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/19
CRDT- 2021/07/02 01:24
PHST- 2021/05/19 00:00 [received]
PHST- 2021/06/09 00:00 [revised]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/07/02 01:24 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/19 00:00 [pmc-release]
AID - jcm10122717 [pii]
AID - jcm-10-02717 [pii]
AID - 10.3390/jcm10122717 [doi]
PST - epublish
SO  - J Clin Med. 2021 Jun 19;10(12):2717. doi: 10.3390/jcm10122717.